Entasis Announces Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 Attack trial.

Click here to learn more
 

Developing Reliable Solutions for Antibacterial Resistance.

Our strategy is to discover, develop and commercialize safe and effective novel molecules that address and overcome mechanisms of antibiotic resistance in specific bacterial pathogens where the medical need is greatest. In this way, we aim to restore health to people affected by these serious pathogens – with exactly the right drug in exactly the right way.

Marching Towards Lasting Progress.

Our programs are designed to have long-term impact where the need is most critical.

Antibiotic Resistance Anywhere

Is a Threat to People Everywhere.

Latest News